Assessment of Isocitrate Dehydrogenase 1 Mutation by Immunohistochemistry in Egyptian Patients with High-grade Gliomas

Essam Ayad; Sylvia Mikhael Ghattas; Rabab Abdel Moneim; Azzam Ismail; Rasha A. Khairy

doi:10.3889/oamjms.2021.5891

Authors

Essam Ayad Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt https://orcid.org/0000-0002-4822-1676
Sylvia Mikhael Ghattas Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt https://orcid.org/0000-0001-5324-0321
Rabab Abdel Moneim Clinical Oncology, Faculty of Medicine, Cairo University, Giza, Egypt
Azzam Ismail Department of Histopathology, Leeds Teaching Hospital, Leeds, England https://orcid.org/0000-0002-9019-6881
Rasha A. Khairy Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt https://orcid.org/0000-0002-9373-354X

DOI:

https://doi.org/10.3889/oamjms.2021.5891

Keywords:

High grade, Gliomas, Isocitrate Dehydrogenase 1, Immunohistochemical

Abstract

BACKGROUND: At present, the classification of central nervous system tumors relies on molecular factors in addition to histologic features to identify many tumor types. This should subsequently results in more accurate diagnosis as well as addressing specific markers of potential prognostic and predictive value.

AIM: This study was conducted to emphasize the importance of including isocitrate dehydrogenase 1 (IDH1) evaluation as a crucial part of the diagnosis and categorization of high-grade glioma cases. This also may help to individualize the treatment of high-grade glioma patients.

MATERIALS AND METHODS: The current study included 60 cases of high-grade gliomas, studied histologically and immunohistochemically for the detection of IDH1 mutation. The results were correlated with different clinicopathologic variables and course of the disease.

RESULTS: IDH1 immunohistochemical expression was positive in 46.67% of the studied high-grade glioma cases. A statistically significant relationship was detected between IDH1 expression and tumor histologic grade as 100% of Grade III anaplastic oligodendroglioma cases and 80% of the Grade III anaplastic astrocytoma cases were IDH1 positive while only 40.4% of Grade IV glioblastoma cases were IDH1 positive (p = 0.03). In addition, patients who were IDH1 mutant were in a better category of response to radiotherapy (p = 0.019) and also to chemotherapy (p < 0.001). Moreover, patients who expressed IDH1 had prolonged overall survival (OS) and progression-free survival than those who showed negative IDH1expression (p < 0.001). On the other hand, no statistically significant relationship was detected between IDH1 expression and patients age, sex, tumor site, tumor size, motor symptoms, sensory symptoms, and increased intracranial tension (p > 0.05).

CONCLUSIONS: It is suggested that IDH1 is a good prognostic marker for gliomas and is a good predictive marker for response to treatment. IDH1 is a promising target for therapy in high-grade gliomas through the emerging IDH1 inhibitors. Immunohistochemical testing for IDH1 is a practical and cost-effective method that should be applied in all glioma cases. Further study on a larger sample size is recommended to validate the current results. Moreover, applying molecular analysis to detect IDH1 mutation is recommended to be able to precisely detect the IDH1 wild-type tumor

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Louis DN, Ohgaki H, Wiestler OD. WHO Classification of Tumours of the Central Nervous System. 4th ed., Vol. 1. Geneva: World Health Organization; 2016. p. 10-76.

Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol. 2014;16(11):1478-83. https://doi.org/10.1093/neuonc/nou097 PMid:24860178 DOI: https://doi.org/10.1093/neuonc/nou097

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547- 60. https://doi.org/10.1007/s00401-012-1016-2 PMid:22810491 DOI: https://doi.org/10.1007/s00401-012-1016-2

Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, et al. DNA methylation in glioblastoma: Impact on gene expression and clinical outcome. BMC Genomics. 2010;11:701. https://doi.org/10.1186/1471-2164-11-701 PMid:21156036 DOI: https://doi.org/10.1186/1471-2164-11-701

Everhard S, Tost J, El Abdalaoui H. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol. 2009;11(4):348-56. https://doi.org/10.1215/15228517-2009-001 PMid:19224763 DOI: https://doi.org/10.1215/15228517-2009-001

Hartmann C, Hentschel B, Wick W. Patients with IDH1 wild type astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognosis effect of higher age: Implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707- 18. https://doi.org/10.1007/s00401-010-0781-z PMid:21088844 DOI: https://doi.org/10.1007/s00401-010-0781-z

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150- 4. https://doi.org/10.1200/jco.2009.21.9832 PMid:19636000 DOI: https://doi.org/10.1200/JCO.2009.21.9832

Wick W, Meisner C, Hentschel B. Prognostic or predictive value of MGMT promotor methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515-22. https://doi.org/10.1212/wnl.0b013e3182a95680 PMid:24068788 DOI: https://doi.org/10.1212/WNL.0b013e3182a95680

Loussouarn D, Le Loupp AG, Frenel JS. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol. 2012;40(6):2058-62. https://doi.org/10.3892/ijo.2012.1404 PMid:22447191 DOI: https://doi.org/10.3892/ijo.2012.1404

Perrech M, Dreher L, Röhn G. Qualitative and quantitative analysis of IDH1 mutation in progressive gliomas by allele-specific qPCR and Western blot analysis. Technol Cancer Res Treat. 2019;18:1533033819828396. https://doi.org/10.1177/1533033819828396 PMid:30943868 DOI: https://doi.org/10.1177/1533033819828396

West H, Jin J. JAMA Oncology Patient Page. Performance status in patients with cancer. JAMA Oncol. 2015;1(7):998. PMid:26335750 DOI: https://doi.org/10.1001/jamaoncol.2015.3113

Kelly C, Majewska P, Ioannidis S, Raza MH, Williams M. Estimating progression-free survival in patients with glioblastoma using routinely collected data. J Neurooncol. 2017;135(3):621- 7. https://doi.org/10.1007/s11060-017-2619-1 PMid:28956223 DOI: https://doi.org/10.1007/s11060-017-2619-1

Mellai M, Caldera V, Annovazzi L, Schiffer D. The distribution and significance of IDH mutations in gliomas. Genes Chromosomes Cancer. 2013;34:416-2. https://doi.org/10.5772/52357 DOI: https://doi.org/10.5772/52357

Mamelak AN, Jacoby DB. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv. 2007;4(2):175- 86. https://doi.org/10.1517/17425247.4.2.175 PMid:17335414 DOI: https://doi.org/10.1517/17425247.4.2.175

Goodenberger ML and Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205(12):613-21. https://doi.org/10.1016/j.cancergen.2012.10.009 PMid:23238284 DOI: https://doi.org/10.1016/j.cancergen.2012.10.009

DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-23. PMid:11150363 DOI: https://doi.org/10.1056/NEJM200101113440207

Li S, Chou AP, Chen W. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013;15(1):57-68. https://doi.org/10.1093/neuonc/nos261 PMid:23115158 DOI: https://doi.org/10.1093/neuonc/nos261

Hartmann, C. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146-57. https://doi.org/10.1158/1078-0432.ccr-13-0017 PMid:23918605 DOI: https://doi.org/10.1158/1078-0432.CCR-13-0017

Combs SE, Rieken S, Wick W. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? Radiat Oncol. 2011;6:115. https://doi.org/10.1186/1748-717x-6-115 PMid:21910919 DOI: https://doi.org/10.1186/1748-717X-6-115

SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103(2):269-73. https://doi.org/10.1111/j.1349-7006.2011.02134.x PMid:22034964 DOI: https://doi.org/10.1111/j.1349-7006.2011.02134.x

Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 2014;16(3):414-20. https://doi.org/10.1093/neuonc/not198 PMid:24305712 DOI: https://doi.org/10.1093/neuonc/not198

Tateishi K, Yamamoto T. IDH-Mutant Gliomas. London: IntechOpen; 2019. p. 84543. DOI: https://doi.org/10.5772/intechopen.84543

Van den Bent MJ, Dubbink HJ, Marie Y. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumours: A report of the European organization for research and treatment of cancer brain tumour group. Clin Cancer Res. 2010;16(5):1597-604. https://doi.org/10.1158/1078-0432.ccr-09-2902 PMid:20160062 DOI: https://doi.org/10.1158/1078-0432.CCR-09-2902

Weller M, Felsberg J, Hartmann C. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-50. https://doi.org/10.1200/jco.2009.23.0805 PMid:19805672 DOI: https://doi.org/10.1200/JCO.2009.23.0805

Yan, H, Parsons D.W, Jin G. IDH1 and IDH2 Mutations in gliomas. N Engl J Med 2009;360(8):765-73. PMid:19228619 DOI: https://doi.org/10.1016/S0513-5117(09)79085-4

Polívka J, Pešta M, Pitule P, Hes O, Holubec L, Polívka J, et al. IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. Oncotarget. 2018;9(23):16462-76. https://doi.org/10.18632/oncotarget.24536 PMid:29662659 DOI: https://doi.org/10.18632/oncotarget.24536

Parsons DW, Jones S, Zhang X. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-12. PMid:18772396

Liu Y, Lang F, Chou FJ, Zaghloul KA, Yang C. Isocitrate dehydrogenase mutations in glioma: Genetics, biochemistry, and clinical indications. Biomedicines. 2020;8(9):294. https://doi.org/10.3390/biomedicines8090294 PMid:32825279 DOI: https://doi.org/10.3390/biomedicines8090294

Tabei Y, Kobayashi K, Saito K. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status. Jpn J Clin Oncol 2021;51:45-53. https://doi.org/10.1093/jjco/hyaa162 DOI: https://doi.org/10.1093/jjco/hyaa162

Jaiswal S, Chaudhary N, Prasad P. Expression of isocitrate dehydrogenase-1 (IDH-1) mutant protein in gliomas. Tech Neurosurg Neurol. 2018;1(3):1-6. DOI: https://doi.org/10.31031/TNN.2018.01.000514

Shaban ZM, Al-Aubaidy SR, Hameedi AD. IDH1 mutation in gliomas in Baghdad by immunohistochemical study. Int J Genet Genomics 2018;6(1):1-7. DOI: https://doi.org/10.11648/j.ijgg.20180601.11

Wang PF, Liu N, Song HW. IDH-1R132H mutation status in diffuse glioma patients: Implications for classification. Oncotarget. 2016;7(21):31393-400. https://doi.org/10.18632/ oncotarget.8918 PMid:27120786 DOI: https://doi.org/10.18632/oncotarget.8918